Roughly 7 in 10 patients responded to therapy.
ONCOLOGY
Fully funded by 
Content independently selected
-
R/R cHL: nivolumab yields favorable outcomes in pooled analysis -
FL: first-line ofatumumab monotherapy safe, active, but unremarkable Limited dose may have limited outcomes.
-
R/R PTCL: phase 3 results for alisertib vs single-agent comparator Potential value for patients with insufficient response to comparators.
-
FDA approves ibrutinib+obinutuzumab for frontline CLL/SLL 77% reduction in risk for disease progression or death.
-
Chronic HBV tied to higher risk for lymphoma, multiple myeloma Population study shows doubled risk for NHL, particularly DLBCL.
-
DLBCL: neutropenia after first R-CHOP cycle predicts OS Grade 4 neutropenia associated with one-third increase in mortality risk.
-
R/R HL: pre-transplant BRESHAP delivers high CR, long-term PFS 7 in 10 patients achieved pre-transplant CR.
-
Breast cancer survivors face excess risk for AML, MDS in French study Novel risks for ALL/LL and MM also identified.
-
GvHD after alloSCT: fluconazole-based prophylaxis reduces IFI Patients with prior history of IFI should receive mold-effective prophylaxis.
-
Hodgkin's lymphoma: interim PET-based therapy improves tolerability Notably fewer serious AEs in patients receiving PET-driven therapy.
-
DLBCL, FL: does residential area affect survival? Interventions needed for residents of nonmetropolitan areas.
-
Richter's transformation: nivolumab + ibrutinib shows promise Confirmation warranted in nonresponders to ibrutinib monotherapy.
-
R/R NHL: gemcitabine-based salvage therapy yields 37% ORR in Israeli study Data show limited success in aggressive disease.
-
Lymphoma: high baseline TMTV, TLG predict worse PFS and OS Chinese meta-analysis of 27 studies finds 3-fold higher risk of poor survival.